Recursion Pharmaceuticals, Inc.
RXRX
$4.94
$0.163.35%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 30.37% | 224.35% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 30.37% | 224.35% | |||
| Cost of Revenue | -1.76% | 36.30% | |||
| Gross Profit | 5.23% | -28.27% | |||
| SG&A Expenses | -14.63% | -29.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.17% | 9.39% | |||
| Operating Income | 7.91% | -4.07% | |||
| Income Before Tax | 15.17% | -13.27% | |||
| Income Tax Expenses | -- | -2,357.14% | |||
| Earnings from Continuing Operations | 15.11% | -13.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 15.11% | -13.18% | |||
| EBIT | 7.91% | -4.07% | |||
| EBITDA | 11.43% | -0.65% | |||
| EPS Basic | 18.06% | 5.58% | |||
| Normalized Basic EPS | 18.16% | 5.53% | |||
| EPS Diluted | 18.06% | 6.05% | |||
| Normalized Diluted EPS | 18.16% | 5.53% | |||
| Average Basic Shares Outstanding | 3.62% | 19.86% | |||
| Average Diluted Shares Outstanding | 3.62% | 19.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||